AD1

AD1 (also known as AD-1 or PUMC-01) is an investigational small molecule drug candidate developed by PUMC Pharmaceutical (Beijing PUMC Pharmaceutical Co., Ltd.) for the treatment of various cancers. It is a derivative of podophyllotoxin and functions as a topoisomerase II inhibitor, a mechanism similar to established chemotherapeutic agents like etoposide. By inhibiting topoisomerase II, AD1 induces DNA double-strand breaks and prevents DNA replication, ultimately leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells. The drug is currently in Phase 1 clinical development, where it is being evaluated for its safety, tolerability, and preliminary efficacy in patients with advanced solid tumors. Notably, the developer also uses the AD-1 code for a separate huperzine A derivative targeting Alzheimer's disease, but the oncology candidate is specifically identified as a podophyllotoxin-based topoisomerase inhibitor.